(19)
(11) EP 3 795 149 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
26.05.2021 Bulletin 2021/21

(43) Date of publication:
24.03.2021 Bulletin 2021/12

(21) Application number: 19802755.9

(22) Date of filing: 14.05.2019
(51) International Patent Classification (IPC): 
A61K 31/341(2006.01)
A61K 31/40(2006.01)
A61P 31/04(2006.01)
C07D 207/36(2006.01)
 A61K 31/381(2006.01)
A61K 45/00(2006.01)
A61P 43/00(2006.01)
C07D 307/68(2006.01)
(86) International application number:
PCT/JP2019/019133
(87) International publication number:
WO 2019/221122 (21.11.2019 Gazette 2019/47)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 14.05.2018 JP 2018093369

(71) Applicant: National University Corporation Tokai National Higher Education and Research System
Nagoya-shi Aichi 464-8601 (JP)

(72) Inventors:
  • ARAKAWA, Yoshichika
    Nagoya-shi, Aichi 464-8601 (JP)
  • WACHINO, Jun-ichi
    Nagoya-shi, Aichi 464-8601 (JP)
  • KIMURA, Kouji
    Nagoya-shi, Aichi 464-8601 (JP)
  • JIN, Wan Chun
    Nagoya-shi, Aichi 464-8601 (JP)
  • SATO, Ayato
    Nagoya-shi, Aichi 464-8601 (JP)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) BETA-LACTAMASE INHIBITOR


(57) An object is to provide a compound having β-lactamase inhibitory activity. The object is achieved by a compound represented by formula (1), typified by a compound in which specific positions of a 5-membered ring having planarity are replaced by sulfamoyl and carboxy groups.